The Indian pharmaceutical sector is witnessing significant growth with global majors expanding their presence in advanced therapies. Recently, the Central Drugs Standard Control Organization (CDSCO) granted approval to Eli Lilly’s India subsidiary for Kisunla (donanemab), a breakthrough treatment for early-stage Alzheimer’s disease. This milestone marks a significant development in neurological care in India.
On the same day, AstraZeneca’s India unit and Sun Pharmaceutical announced an exclusive brand partnership to increase access to sodium zirconium cyclosilicate (SZC) for hyperkalaemia, a condition characterized by high potassium levels in the blood. This partnership underscores the growing efforts to bring cutting-edge medicines to Indian patients.
These developments demonstrate the increasing focus of global pharmaceutical companies on the Indian market, which is driven by the country’s large patient population and growing demand for innovative treatments. The Indian government has also been actively promoting the growth of the pharmaceutical sector, with initiatives such as the “Pharma Vision 2020” plan, which aims to make India a hub for pharmaceutical manufacturing and research.
The approval of Kisunla and the partnership between AstraZeneca and Sun Pharmaceutical are expected to improve access to advanced therapies for Indian patients, particularly in areas such as neurology and cardiology. The Indian pharmaceutical sector is expected to continue growing, driven by the increasing demand for innovative treatments and the government’s efforts to promote the sector.
The growth of the pharmaceutical sector in India is also expected to attract more foreign investment, with many global companies looking to tap into the country’s large patient population and growing healthcare market. The sector is also expected to create new job opportunities and drive economic growth in the country. Overall, the developments in the Indian pharmaceutical sector are positive and are expected to have a significant impact on the country’s healthcare landscape.